Segment Data (Schedule of Segment Reporting Information by Business Segment) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Dec. 27, 2013		Dec. 28, 2012
Net sales	$ 540.2		$ 504.0
Operating income	73.1		36.8
Intangible asset amortization	(8.8)		(8.9)
Restructuring and related charges, net	(8.1)		(1.0)
Separation costs	(2.2)		(12.0)
Restructuring related accelerated depreciation	(0.1)		(0.8)
Specialty Pharmaceuticals
Restructuring and related charges, net	0		(0.7)
Global Medical Imaging
Restructuring and related charges, net	(8.1)		(0.3)
Operating Segments
Net sales	528.1	[1]	489.9	[1]
Operating income	117.4		84.1
Operating Segments | Specialty Pharmaceuticals
Net sales	309.5		260.2
Operating income	113.0		35.0
Operating Segments | Global Medical Imaging
Net sales	218.6		229.7
Operating income	4.4		49.1
Corporate, Non-Segment
Net sales	12.1	[2]	14.1	[2]
Corporate and allocated expenses	(25.2)	[3]	(25.4)	[3]
Intangible asset amortization	(8.8)		(8.9)
Restructuring and related charges, net	(8.1)	[4]	(1.0)	[4]
Separation costs	$ (2.2)		$ (12.0)

[1] Amounts represent sales to external customers.

[2] Represents products that were sold to Covidien, our former parent company, which is discussed in Note 14.

[3] Includes administration expenses and certain compensation, environmental and other costs not charged to the Company's operating segments.

[4] Includes restructuring-related accelerated depreciation of $0.1 million and $0.8 million for the three months ended December 27, 2013 and December 28, 2012, respectively